Chris Ryan

Articles

FDA OKs Omidubicel Priority Review For Patients in Need of Allogeneic HSCT

August 07, 2022

The biologics license application for omidubicel has been granted priority review and will be assessed as a potential treatment for patients with blood cancer who require allogeneic hematopoietic stem cell transplant.